Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2021-06-09 Director's Dealing
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-06-09 English
FORM 4
Director's Dealing
2021-06-09 English
FORM 4
Director's Dealing
2021-06-09 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a regulatory communication related to securities registration and does not contain financial statements, management discussion, or report data. The document length is short (911 characters) and it is a formal request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-06-09 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable for more specific classification.
2021-06-04 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 26, 2021, by Moleculin Biotech, Inc. The key content is the submission of matters to a vote of security holders at the 2021 Annual Meeting of Stockholders, including election of directors and ratification of the independent auditor. The document provides detailed voting results for each proposal. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4282 characters, which is short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). It is not a management change announcement, nor an earnings release or other report type. Hence, the correct classification is DVA with high confidence.
2021-05-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.